What is TORPIDO2?
The TORPIDO2 study is a clinical trial that compares 2 commonly
used levels of oxygen for respiratory care in the delivery room for
babies born at less than 29 weeks gestation to see if one has more
benefits without increasing risks in the short and the long
What are we trying to find out?
The main question we are trying to answer is whether lower or
higher oxygen in the delivery room is better when comparing
survival without major disability at 2 years old.
We will also compare short term hospital outcomes such as
bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP),
necrotising enterocolitis (NEC), sepsis, patent ductus arteriosus
(PDA), duration of hospital stay, all-cause mortality, respiratory
morbidity and complication, spontaneous intestinal perforation and
Coordination, Sponsorship and Funding
This multi-centre trial is coordinated by the NHMRC Clinical
Trials Centre (CTC), University of Sydney and is sponsored by the
University of Sydney. Funding is provided by the National Health
and Medical Research Council (NHMRC).
This trial is registered with the Australian New Zealand
Clinical Trials Registry (ANZCTR), registration number
Below is a short introduction to the trial presented by Melinda
Cruz, Founder and CEO of Miracle Babies Foundation.